Obesity and asthma are 2 of the most common pediatric diseases, particularly among African American and Hispanic subjects. 1, 2 Obesity is a known predictor of childhood asthma, 3 and obesity-related asthma is distinct from asthma in normalweight patients. 4 Obese children with asthma have higher disease morbidity, 5 lower pulmonary function, 6 and lower responsiveness to bronchodilators compared with normal-weight children with asthma. 7 Although truncal adiposity 8 ; metabolic abnormalities, including insulin resistance and dyslipidemia 9, 10 ; and systemic inflammation 6 have been postulated, the precise mechanisms underlying pediatric obesity-related asthma are not well elucidated.
Obese asthmatic children have evidence of nonatopic T H 1-polarized systemic inflammation, 6, 11 which is associated with pulmonary function deficits 6, 11 and differs from atopic inflammation associated with classic childhood asthma. 12 Moreover, insulin resistance mediates the association of T H 1 polarization with pulmonary function deficits. 11 Although extensive investigation of immune pathways in the context of atopic asthma 13 has led to the development of targeted therapy, including omalizumab, 14 the lack of a similar understanding of mechanisms underlying nonatopic immune responses, as observed in the context of obesity-related asthma, 6, 11 is associated with limited therapeutic options for obese children with asthma.
To address these gaps in knowledge, we compared the CD4 1 (T H ) cell transcriptome of obese asthmatic children with that of normal-weight asthmatic children of African American and Hispanic ethnicity to elucidate the mechanistic immune pathways underlying T H 1 polarization. We hypothesized that gene expression in CD4 1 T cells from obese asthmatic patients differs from that in normal-weight asthmatic patients, and its investigation will allow for identification of key molecules underlying the nonatopic T H 1-polarized inflammation associated with the obese asthma phenotype.
METHODS

Study population
Two study cohorts comprised of obese and normal-weight African American and Hispanic children aged 7 to 11 years with asthma were recruited from clinics at Children's Hospital at Montefiore between July 2013 to June 2016. The first discovery cohort comprised 42 children, including 21 obese and 21 normal-weight children with asthma. The second validation cohort comprised 20 children, including 10 obese and 10 normal-weight children with asthma. Obesity was defined as a body mass index of greater than the 95th percentile for age and sex. Asthma was classified based on the clinical diagnosis made by a health care provider that was confirmed on
Abbreviations used
FRC: Functional residual capacity FVC: Forced vital capacity GTP: Guanosine triphosphate MAPK: Mitogen-activated protein kinase mTOR: Mammalian target of rapamycin qRT-PCR: Quantitative RT-PCR RNA-seq: RNA sequencing RV: Residual volume TLC: Total lung capacity electronic medical records. All participants completed a research study visit at the Clinical Research Center at the Montefiore Medical Center where they underwent anthropometric measurements, allergy skin prick testing to 8 allergens (tree mix, grass mix, ragweed, dust mite [Dermatophagoides pteronyssinus], cockroach, mouse, cat, and mold), and fasting phlebotomy, as previously described. 6 Pulmonary function testing was abstracted from the medical charts. It was performed per American Thoracic Society guidelines and included spirometry and lung volume quantification by nitrogen washout, as previously described. 6 Percent predicted values were calculated for spirometric indices by using the National Health and Nutrition Examination Survey prediction equations and for lung volume indices by using equations developed by the American Thoracic Society workshop, as previously described. 6 The institutional review board at Albert Einstein College of Medicine approved the study.
Study measures
Separation of CD4
1 T cells. Given the association of insulin resistance with T H 1 polarization, 11 we processed fasting blood for cell and serum separation. PBMCs were separated by using the Ficoll Hypaque method. CD4
1 T cells were isolated from PBMCs by means of negative selection with magnetic beads (EasySep; Stem Cell Technologies, Tukwila, Wash) to avoid any ex vivo CD4 1 T-cell stimulation. The CD4 1 T-cell purity was 95% to 98%, as confirmed by means of flow cytometry (see Fig E1 in this article's Online Repository at www.jacionline.org). T-cell proportions did not differ between the obese (26.6% 6 5%) and normal-weight (27.1% 6 7.4%) samples. Unstimulated T cells were used for transcriptome quantification to elucidate differential gene expression more reflective of in vivo conditions. Serum separated from fasting blood was used for insulin quantification by using a radioimmunoassay (Millipore, Temecula, Calif) on a Wizard2 gamma counter (PerkinElmer, Waltham, Mass). Lipids were quantified by using an enzymatic immunoassay and measured on an AU400 Chemistry Autoanalyzer (Beckman Coulter, Fullerton, Calif). Alignment and analysis of directional RNA-seq libraries. All bioinformatics analyses were performed on a highperformance computing cluster at Albert Einstein College of Medicine. Several quality control steps were taken to ensure accuracy of the analyzed results. Picard tools, version 1.119, 16 was used to demultipex and generate FASTQ files, which were then trimmed for poor-quality bases and adaptor sequences by using Trim Galore!, version 0.3.7.
17 By using STAR, version 2.5.1b, 18 and gene annotations from Ensembl release 83, 19 the trimmed reads were aligned to the UCSC hg38 human genome assembly, and gene counts were generated.
Gene counts were normalized, and between-group comparison was performed with DESeq 20 on R statistical software, version 3.2.2. Using principal component analysis, we investigated the contribution of biological and technical covariates in the variance of normalized counts between the study groups (Fig 1) . Although fasting insulin level was the only biological variable associated with variance, several technical factors, including total number of reads, protein coding reads, percentage of duplicate reads, and sequencing batch were determined to significantly contribute to the variance in the gene counts. There was no association of lipids (high-density lipoprotein, lowdensity lipoprotein, or triglycerides) with gene-count variance. Given the association of gene-count variance with both biological and technical factors, multivariate linear regression analysis was conducted to identify betweengroup differential gene expression, adjusting for the biologic and each of the technical factors. Age, sex, and ethnicity were included in the model for their demographic significance. Genes identified by means of multivariate analysis to be differentially expressed among obese asthmatic patients with a between-group P value of less than .05 and a false discovery rate q-value of less than 0.05 were retained as high confidence differentially expressed genes for verification and validation studies. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database, version 10, 21 was used to identify relationships between differentially expressed genes. Gene expression data and patients' characteristics are available at Gene Expression Omnibus number GSE86430.
Verification and validation of directional RNA-seq results. A subset of the high-confidence differentially expressed genes was verified by using quantitative RT-PCR (qRT-PCR) on RNA isolated from CD4 1 T cells from 32 children from the discovery cohort (16 children per study group). These genes and additional related genes were further validated in the validation cohort. Verification and validation was done by means of quantitative PCR by using the TaqMan gene expression assay with commercially available quantitative PCR primers (Thermo Fisher) and analyzed by using the DD cycle threshold method.
Protein quantification as additional validation of differential gene expression. CDC42EP4 and DOCK5 proteins were quantified to additionally validate differential gene expression, and phosphorylated and total p38 and S6K1 proteins were quantified as evidence for mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) pathway activation in T-cell lysates from a subset of 5 samples from obese asthmatic patients and 4 samples from normal-weight children with asthma and normalized to actin. All antibodies, except for CDC42EP4 (Thermo Fisher Scientific), were purchased from Santa Cruz Biotechnology (Dallas, Tex). Western blot experiments were run as per protocol (Bio-Rad Laboratories, Hercules, Calif). Immunoblot band intensity was quantified with ImageJ software (National Institutes of Health, Bethesda, Md).
Statistical analysis
Clinical characteristics were compared between obese and normal-weight asthmatic patients by using the Student t test for continuous variables and the x 2 or Fisher exact test for categorical variables. Between-group comparison of the log 10 transformed differential gene expression by using qRT-PCR was done with the Student t test. Normalized gene counts of the high-confidence differentially expressed genes were log transformed for correlation analysis with pulmonary function indices. Statistical analysis was performed on STATA software, version 14 (StataCorp, College Station, Tex).
RESULTS
Study population
The clinical characteristics of the discovery and validation cohort are summarized in Tables I and II, respectively. 22 Obese asthmatic children did not differ in age, sex, or ethnicity distribution from normal-weight asthmatic children in either the discovery or validation cohort. More normal-weight than obese children had evidence of atopic sensitization in the discovery cohort. In keeping with prior studies, obese children in the discovery cohort had lower percent predicted forced vital capacity (FVC), FEV 1 , residual volume (RV), and functional residual capacity (FRC) and RV/total lung capacity (TLC) ratio compared with normalweight children with asthma. In the validation cohort, although RV, RV/TLC ratio, and FRC, were lower among obese children compared with normal-weight children, only FRC was significantly different between the 2 groups. Pulmonary function values were consistent between the obese asthmatic group in the 2 cohorts, other than percent predicted RV, but there was greater variability in FVC, FEV 1 , and RV/TLC ratio between the 2 normalweight groups.
Analysis and validation of differential CD4
1 T-cell gene expression Univariate analysis by using DESeq revealed differential gene expression of 1371 genes in CD4
1 T cells from obese asthmatic compared with normal-weight patients, with more genes being upregulated in the obese compared with normal-weight asthmatic patients (Fig 2, A) . After adjusting in multivariate regression analysis for the biological and technical factors associated with genecount variance, 319 genes were differentially expressed among obese compared with normal-weight asthmatic children (between-group P < .05, q-value < 0.05; Fig 2 , B, and see Table E1 in this article's Online Repository at www.jacionline.org). Of these, 89 genes overlapped between the initial DESeq analysis and multivariate analysis (see Table E2 in this article's Online Repository at www.jacionline.org). Gene network analysis of these 89 genes revealed CDC42 to be at the hub of the differentially expressed genes (Fig 3) . Moreover, 24 of the 89 upregulated genes among obese asthmatic patients were associated with modulation of the small guanosine triphosphate (GTP)-binding proteins CDC42 and RAC1 (Table III) . Of particular relevance were VAV2, DOCK5, PAK3, PLD1, CDC42BPB, and CDC42EP4, which either interact directly with the CDC42 protein (CDC42EP4), are upstream modulators (VAV2 and DOCK5), or are downstream targets of CDC42 (PAK3, PLD1, and CDC42BPB). We verified the expression of CDC42EP4 because it directly interacts with CDC42, and DOCK5 and VAV2, its upstream modulators, using qRT-PCR (Fig 4) . Although expression of CDC42EP4 and DOCK5 was significantly higher among obese asthmatic patients, there was a nonsignificant trend of higher VAV2 expression in obese asthmatic patients (Fig 4 and www.jacionline.org). Because several differentially expressed genes were associated with both CDC42 and RAC1 activation, we quantified RAC1 expression and found no differential expression (Fig 4) . Therefore we focused on validating these differentially expressed genes and additional downstream genes (PAK3, PLD1, MLK3, and cRaf1) in the validation cohort (Fig 5) as confirmation of upregulation of the CDC42 pathway in obese asthmatic CD4
1 T cells. Although MLK3, PAK3, and PLD1
were upregulated in obese asthmatic patients, cRaf1 was not differentially expressed ( Fig 5) .
Immunoblot analysis was done to confirm that higher mRNA expression of CDC42EP4 and DOCK5 translated into higher protein expression. In keeping with the RNA-Seq and quantitative PCR data, we found a trend toward higher levels of these 2 proteins, although the trend did not reach statistical significance (see Fig E3 in www.jacionline.org). Similarly, there was a nonsignificant trend toward higher levels of S6K1 phosphorylation in T cells from obese asthmatic patients, which was supportive of activation of the CDC42-mTOR signaling pathway.
To elucidate clinical significance, we correlated gene transcript counts with pulmonary function variables. We found an inverse association between log-transformed normalized gene counts of CDC42EP4 and DOCK5 and FEV 1 /FVC ratios only among obese asthmatic patients (Fig 6) , ascribing clinical relevance to the differential gene expression.
DISCUSSION
Our study provides novel evidence that the transcriptome of CD4 1 T cells derived from obese asthmatic children differs from that of CD4 1 T cells from children with normal-weight asthma. Specifically, we found that several genes associated with the small GTP-binding protein CDC42 were upregulated in T cells from obese children with asthma. Although VAV2 and DOCK5 are upstream of and activate CDC42, CDC42EP4 interacts directly with CDC42, and CDC2BPB, PAK3, and PLD1 are downstream effectors, mediating the different effects of this ubiquitous GTP protein. Furthermore, CDC42EP4 and DOCK5 gene transcript counts correlated with lower airway obstruction, suggesting that the CDC42 pathway might have clinical implications in pediatric obesity-related asthma.
Few of these genes have been previously studied in the context of inflammation in asthma or obesity. 23 However, the role of CDC42 and its related proteins has been researched extensively in the context of T-cell physiology. VAV2 and DOCK5, which are upregulated in T cells from obese asthmatic patients, are guanine exchange factors that activate CDC42. 24 VAV2 is ubiquitously expressed and associated with activation of CDC42 25 and its downstream c-JUN transcription factor, 25 leading to CDC42-mediated activation of the MAP kinase pathway. 26 DOCK proteins are less well studied in T cells. Although DOCK5, a member of DOCK family A, 27 is classically associated with activation of RAC1, 28 it influences the degranulation response in mast cells through the NCK-AKT pathway independent of the RAC1 activation, 29 suggesting that it might have additional effects on immune cells. Because our study is the first to identify upregulation of DOCK5 and its association with CDC42 in T cells, further investigation of its effects and related downstream molecules are needed to identify its role in T cells.
We also confirmed upregulation of downstream targets of CDC42, including PAK3, MLK3, and PLD1 but not cRaf1. PAK3, with CDC42, plays a role in immunologic synapse formation [30] [31] [32] and is associated with activation of MAPK and mTOR immune pathways. [33] [34] [35] Higher MLK3 expression also supports downstream activation of the MAPK pathway as a potential mechanism underlying T H 1 polarization among obese asthmatic children. Similarly, PLD1 activation by CDC42 36 mediates S6K1 activation in the mTOR pathway, 34 which regulates T H 1 and T H 17 differentiation. 37 Quantified in resting cells, we found a small nonsignificant trend for higher phosphorylated S6K1 levels in T cells from obese asthmatic patients. Together, upregulated gene expression of upstream guanine exchange factors and downstream effectors provide evidence of activation of CDC42-related pathways that have been associated with T H cell activation and might explain the differentiation bias toward a T H 1 lineage, 37 a phenotype observed among obese asthmatic children. 6, 11 Moreover, the inverse association of CDC42EP4 and DOCK5 gene counts with FEV 1 /FVC ratio uniquely in obese asthmatic patients provides additional evidence of its relevance in the obese asthma phenotype.
In light of the association of nonatopic systemic inflammation with disease burden in obese asthmatic adults 38 and children, 6, 11 we speculate that CDC42 activation in T cells from obese asthmatic patients might play several roles, including skewing of Tcell differentiation to a T H 1/T H 17 profile, increased T-cell tissue recruitment by facilitating transmigration, and T-cell activation. Because these pathways are distinct from those activated in patients with atopic asthma, 39 our findings begin to identify immune pathways associated with nonatopic immune responses in patients with the obese asthma phenotype. Activation of Rho GTPases, including CDC42, has been proposed to underlie T-cell activation in patients with T H 1-mediated autoimmune diseases, such as lupus. 40 Validation of our findings would support potential extension of therapeutics used for autoimmune diseases to obesity-related asthma. Although the direct mechanism by which circulating T cells influence pulmonary physiology in obese patients with asthma is not known at this time, we hypothesize that T cells might increase neutrophilic airway inflammation 41 or influence airway smooth muscle contractility and proliferation, 42 mechanisms that have been proposed to underlie the obese asthma phenotype and warrant further investigation. MA plot of fold change and mean gene expression by using DESeq analysis before adjustment for biological and technical covariates (univariate analysis; A) and after adjustment for biological and technical covariates (multivariate analysis; B). Red dots denote differentially expressed genes among obese asthmatic patients at a false discovery rate q-value of less than 0.05.
We have previously reported an association between insulin resistance and systemic T H 1 polarization in urban minority children. 11 In the current study insulin was significantly associated with gene-count variance. T-cell activation is associated with aerobic glycolysis, 43 increased cellular glucose uptake caused by translocation of glucose transporter 1 (GLUT1), 44 and de novo expression of the insulin receptor on the cell surface, 45 suggesting a metabolic role for insulin in T-cell activation. Because the insulin signaling pathway uses CDC42 for glucose transport in adipocytes, 46 we hypothesize that the same mechanism can be used to address the activated T cell's increased glucose needs. 43 Thus upregulation of the CDC42 pathway identifies a need for further exploration of these immunometabolic pathways in patients with chronic diseases, such as obesity-related asthma.
Our study has several strengths. It is the first study to investigate the T H cell transcriptome using directional RNA-seq and identifies the CDC42 pathway as a key upregulated pathway in obese asthmatic children that is associated with lower airway obstruction. The T H cell transcriptomic findings were validated in a separate cohort of 10 obese and 10 normal-weight children with asthma. We also identified the influence of technical and biological covariates on differential gene expression in a disease state, highlighting the importance of addressing these to allow for the identification of high confidence genes. These findings in negatively selected unstimulated T cells unmodified by any external mitogenic influences are more reflective of in vivo responses and are novel because prior studies of unstimulated T cell transcriptome did not find differences between cases and control subjects. 47 However, there are certain limitations. Asthma diagnosis in our cohort was based on physician diagnosis rather than objective assessment of airway reactivity. We found small fold differences in the gene expression and nonsignificant differences in the corresponding and downstream proteins. Because these cells were derived from obese children with wellcontrolled asthma in the absence of a recent exacerbation, it is unlikely that the cells would be markedly activated with increased protein levels, as can be observed in the setting of an asthma exacerbation. Furthermore, the lack of an obese nonasthmatic control group limited the understanding of the extent to which differential gene expression was driven by obesity alone. In addition, our study is cross-sectional in nature, and therefore a cause-effect relationship could not be derived. Nonetheless, the upregulation of several genes associated with the CDC42 pathway upstream of both the MAPK and mTOR pathways suggests that these pathways might be poised for activation in the setting of poor disease control or an exacerbation and thereby provides direction for further investigation to identify the key molecules that might be associated with nonatopic T H 1 systemic inflammation in patients with obesity-related asthma. In summary, we found upregulation of several genes associated with the small GTP protein CDC42, which is involved in many Tcell functions, including antigen recognition through the immunologic synapse, intracellular transport and vesicle formation for cytokine release, and T-cell activation with activation of the MAPK and mTOR pathways. These genes and their (Fig 4) , differential expression of additional genes downstream of CDC42, including MLK3 and cRAF1, were investigated. Although expression of MLK3 was higher in T H cells from obese asthmatic patients, that of cRAF1 did not differ between T H cells from obese and thope from normal-weight asthmatic patients. *P < .05, **P < .01, and ***P < .005. associated pathways provide direction for further investigation of key regulatory molecules underlying the nonatopic T-cell inflammation in obese asthmatic patients that can serve as therapeutic targets for pediatric obesity-related asthma.
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Key messages
d T H cells from obese asthmatic children have a distinct transcriptome when compared with T H cells from normal-weight children.
d Expression of genes related to CDC42, a GTP protein, which plays a role in T-cell activation, was upregulated in T H cells from obese asthmatic children. were quantified based on staining with anti-human CD4-allophycocyanin H7 antibody in freshly separated PBMCs (Fig E1, B) and T cells isolated by means of negative selection (Fig E1, C) . 
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FIG E3.
Western blot analysis of proteins corresponding to upregulated high-confidence genes and those in downstream MAPK and mTOR pathways. CDC42PE4 and DOCK5 trended toward higher levels in in obese asthmatic samples. Similarly, p-S6K1 levels trended toward higher in obese asthmatic patients. However, none of these differences reached statistical significance.
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